NCT06223906 A Registry Study of Biomarkers in Heart Valve Disease
| NCT ID | NCT06223906 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Institute of Heart, Lung and Blood Vessel Diseases |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 200,000 participants |
| Start Date | 2016-01-01 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200,000 participants in total. It began in 2016-01-01 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the elderly and is on the rise. The primary conditions within this category are Aortic Stenosis and Mitral Regurgitation. These conditions are linked to considerable morbidity and mortality, presenting a formidable challenge in optimizing treatment strategies. Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study is to identify biomarkers involved in this disease using multi-omics approaches
Eligibility Criteria
Inclusion Criteria: * Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital Exclusion Criteria: * Age \< 18 years * Failure to obtain medical records and ultrasound data * Refuse follow-up
Contact & Investigator
Jie Du, Dr
STUDY DIRECTOR
The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases
Frequently Asked Questions
Who can join the NCT06223906 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06223906 currently recruiting?
Yes, NCT06223906 is actively recruiting participants. Contact the research team at wangyuan980510@163.com for enrollment information.
Where is the NCT06223906 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06223906 clinical trial?
NCT06223906 is sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases. The principal investigator is Jie Du, Dr at The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases. The trial plans to enroll 200,000 participants.